Search Results - "Ryšavá, R"

Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A by Závada, J, Pešičková, S Sinikka, Ryšavá, R, Horák, P, Hrnčíř, Z, Lukáč, J, Rovenský, J, Vítová, J, Havrda, M, Rychlík, I, Böhmova, J, Vlasáková, V, Slatinská, J, Zadražil, J, Olejárová, M, Tegzova, D, Tesar, V

“…Objective To evaluate the extended follow-up of the CYCLOFA-LUNE trial, a randomized prospective trial comparing two sequential induction and maintenance…”
Get full text

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study by Zavada, J., Pešickova, SS, Ryšava, R., Olejarova, M., Horák, P., Hrnčíř, Z., Rychlík, I., Havrda, M., Vítova, J., Lukáč, J., Rovensky, J., Tegzova, D., Böhmova, J., Zadražil, J., Hána, J., Dostál, C., Tesar, V.

“…Intravenous cyclophosphamide is considered to be the standard of care for the treatment of proliferative lupus nephritis. However, its use is limited by…”
Get full text

Results of autologous stem cell transplantation for AL amyloidosis in one Czech center by Ryšavá, R., Straub, J., Vacková, B., Ko en, J., Trn ný, M., Potyšová, Z., Špi ka, I.

Get full text

Can adequate treatment influence the postembolization syndrome and cytokine release in patients undergoing iatrogenic renal artery embolization? by Ryšavá, R, Hrušková, Z, Tesař, V, Křivánek, J, Haluzík, M, Merta, M, Vítek, L

“…The complete renal artery embolization is an alternative to surgical nephrectomy in seriously ill patients. Iatrogenic embolization can be used in many…”
Get more information

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury by Steiner, N., Abdel Hamid, A., Kronbichler, A., Neuwirt, H., Myslivecek, M., Kollar, M., Lachmanova, J., Rysava, R., Hruskova, Z., Spicka, I., Willenbacher, W., Nachbaur, D., Wolf, D., Tesar, V., Gunsilius, E.

“…Background In patients with multiple myeloma (MM) free light chain-induced cast nephropathy is a serious complication associated with poor survival…”
Get full text

Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis by Hladinova, Z., Hruskova, Z., Svobodova, B., Malickova, K., Lanska, V., Konopásek, P., Jancova, E., Rysava, R., Edelstein, C. L., Tesar, V.

“…Objective. ST2, a member of the interleukin-1 receptor family, is selectively expressed on Th2 cells and mediates important Th2 functions. IL-33 is a specific…”
Get full text

Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters by Chocova, Z., Hruskova, Z., Mareckova, H., Svobodova, B., Duskova, D., Bednarova, V., Jancova, E., Rysava, R., Tesar, V.

“…Rituximab (RTX) was reported effective in ANCA-associated vasculitis (AAV). We aimed to evaluate clinical efficacy of RTX in AAV along with its impact on…”
Get full text

Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil by Svobodova, B, Hruskova, Z, Rysava, R, Tesar, V

Get full text

DNA analysis of renal electrolyte transporter genes among patients suffering from Bartter and Gitelman syndromes: summary of mutation screening by Urbanova, M, Reiterova, J, Stekrova, J, Lnenicka, P, Rysava, R

“…Patients with renal diseases associated with salt-losing tubulopathies categorized as Gitelman and classic form of Bartter syndrome have undergone genetic…”
Get full text

A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population by Merta, Miroslav, Reiterova, Jana, Ledvinova, Jana, Poupětová, Helena, Dobrovolný, Robert, Ryšavá, Romana, Maixnerová, Dita, Bultas, Jan, Motáň, Jiří, Slivkova, Jitka, Sobotova, Doris, Smrzova, Jana, Tesař, Vladimir

“…Background. Fabry disease (FD) is a genetic disorder characterized by accumulation of trihexosylceramide in lysosomes of various tissues leading to multiorgan…”
Get full text

Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre by Potyšová, Z., Merta, M., Tesař, V., Jančová, E., Honsová, E., Ryšavá, R.

“…Renal amyloid involvement results, especially, from AL (primary) or AA (secondary) amyloidosis. The extent of amyloid tissue deposits in the kidneys and the…”
Get full text

Current treatment strategies in ANCA-positive renal vasculitis—lessons from European randomized trials by Tesař, V., Říhová, Z., Jančová, E., Ryšavá, R., Merta, M.

“…Antineutrophil cytoplasmic antibody (ANCA)-positive renal vasculitis is the most common cause of rapidly progressive (crescentic) glomerulonephritis. Its…”
Get full text

The influence of vascular endothelial growth factor (VEGF) polymorphism on the progression of chronic glomerulonephritides by Safránková, H, Merta, M, Reiterová, J, Stekrová, J, Maixnerová, D, Ryšavá, R, Skibová, J, Tesař, V

“…Vascular endothelial growth factor is an important mediator in maintaining normal kidney functions. In addition, several lines of evidence show that…”
Get full text

Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients by Ryšavá, R., Merta, M., Špička, I., Tesař, V.

“…Primary (AL) and secondary (AA) amyloidosis are systemic diseases characterized by a process of amyloid deposition in many organs with unsatisfactory survival…”
Get full text

Genetics of diabetic nephropathy by Merta, M., Reiterova, J., Ryšavá, R., Kmentová, D., Tesař, V.

“…Diabetic nephropathy (DN) develops in ~40% of type 1 diabetic patients and is a leading cause of end-stage renal failure. Its rate of progression varies…”
Get full text

SAT-149 NATION-WIDE CZECH REGISTRY OF CKD 4-5 PREDIALYSIS PATIENTS (RIP) – 10 YEARS DATA SURVEY by Rychlik, I., Jeřábková, K., Dusilová Sulková, S., Táborský, P., Vojanec, V., Ryšavá, R., Viklický, O., Tesař, V.

Get full text

Mercury intoxication from skin ointment containing mercuric ammonium chloride by PELCLOVA, D, LUKAS, E, RIDZON, P, URBAN, P, PREISS, J, RYSAVA, R, LEBENHART, P, OKROUHLIK, B, FENCLOVA, Z, LEBEDOVA, J, STEJSKALOVA, A

“…A one-year follow-up was performed of a 21-year-old man with a 16-year history of diabetes mellitus type I, who had been using ointment containing 10% mercuric…”
Get full text

The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy by Maixnerová, D, Merta, M, Reiterová, J, Stekrová, J, Rysavá, R, Obeidová, H, Viklický, O, Potmĕsil, P, Tesar, V

“…The clinical course of chronic renal diseases and their progression to ESRF is highly variable. Different candidate gene polymorphisms have been advocated as…”
Get full text

Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease by Merta, M, Reiterová, J, Rysavá, R, Tesar, V, Závada, J, Jáchymová, M, Zima, T

“…The pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease (ADPKD) is complex and likely dependent on interaction of…”
Get full text

The influence of two megsin polymorphisms on the progression of IgA nephropathy by Maixnerová, D, Merta, M, Reiterová, J, Stekrová, J, Rysavá, R, Viklický, O, Obeidová, H, Tesar, V

“…The clinical course of chronic renal diseases and their progression to ESRD is highly variable. The strongest predictors of poor outcome of IgAN involve…”
Get full text